Skip to content
Medical Health Aged Care

Intriguing connections between Alzheimer’s disease and other common conditions

The Florey 2 mins read
Dr Nicholas Pan

A Florey study has found that while some medical conditions appear to increase our likelihood of developing Alzheimer’s disease, others appear to decrease the odds. 

The study, led by Dr Yijun (Nicholas) Pan and Dr Liang Jin, analysed data from 2,443 older Australians living in Melbourne or Perth who are part of the Australian Imaging, Biomarker and Lifestyle (AIBL) study, an internationally recognised cohort for dementia research. 

“We found anxiety and other neurological disorders are associated with increased likelihood of Alzheimer’s disease,” Dr Pan said.  

“People with anxiety and neurological disorders are 1.5 and 2.5 times more likely to have Alzheimer’s disease. For people with anxiety, males have higher odds than females of developing Alzheimer’s disease.”  

The study, published in Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, found several medical conditions are linked to lower odds of Alzheimer’s disease, such as arthritis, cancer, gastric complaints, and high cholesterol. The reasons for the connections were complex, Dr Pan said.  

Dr Pan said the protein p53, which has been shown by others to regulate amyloid-beta mediated neuron death seen in Alzheimer’s disease, is also known to lose its function with cancer, providing a possible explanation for the connection between the two conditions.  

“We need further research to understand whether these diseases interfere with the evolution of Alzheimer’s or whether there might be other reasons. The medications or treatments used for these diseases may possibly contribute to this observation,” he said.  

The study reported no significant association was observed between depression, falls or stroke and Alzheimer’s disease. 

Dr Pan said the research provided a useful insight into the complex interconnections between the many conditions at play for most people with Alzheimer’s disease. 

"This is the first study to assess 20 comorbidity associations with cognitive impairment using a single Australian dataset, which allowed us to fully consider how these conditions affect the likelihood of developing Alzheimer’s disease.  

“We also studied whether age, gender, smoking, education, alcohol consumption, and the APOE gene – believed to be connected to Alzheimer’s - affects these associations. Our study indicates a new opportunity for biologists to study the links between these 20 conditions with Alzheimer's disease.  

“This work also provides valuable epidemiological evidence to clinicians, which may help them to evaluate one's risk of developing Alzheimer's disease," Dr Pan said. 

About us:

The Australian Imaging, Biomarker and Lifestyle (AIBL) study aims to investigate the natural history of Alzheimer’s disease (AD), from preclinical onset to development of dementia. The study collects biospecimens, brain images and clinical and cognitive data into its databank with the aim to discover which biomarkers, cognitive characteristics, and health and lifestyle factors predict development and progression of symptomatic AD. 

Lifestyle data is also collected on AIBL participants, with an aim to find modifiable risk factors for disease onset and progression. Furthermore, disease onset and rates of change are investigated using extensive genetic datasets. 

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementiaepilepsymental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere. 

Find out more about us on our website:  

Contact details:

Kathryn Powley, Media and Communications Manager | 0456 666 271 


More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.